PULSE BIOSCIENCES, INC. 8-K

What Happened
Pulse Biosciences, Inc. (PLSE) filed an 8‑K on April 27, 2026 disclosing a press release and updated investor deck issued April 25, 2026. The company announced additional key findings from its first‑in‑human study of the nPulse Cardiac Catheter System to treat atrial fibrillation, presented at Heart Rhythm 2026 in Chicago by Dr. Vivek Reddy of Mount Sinai Fuster Heart Hospital.

Key Details

• 6‑month Holter procedural success: 100% of evaluable patients (95/95).
• 1‑year Holter procedural success: 96% of evaluable patients (51/53).
• 1‑year Kaplan‑Meier estimate freedom from AF/AFL/AT: 90%.
• Procedural performance averages: left atrial dwell time 18.6 ± 13.0 min; total procedure time 60.2 ± 27.7 min; fluoroscopy time 9.4 ± 5.9 min; average applications per patient for PVI 12.3 ± 2.6.
• Safety: low serious adverse event rate with 1.7% (3/177) of subjects experiencing a SAE related to the primary safety endpoint.
• Company posted an updated investor presentation (Investor Deck) on April 25, 2026 and expects to use it in investor/analyst presentations.

Why It Matters
These data provide clinical evidence on the effectiveness, procedural efficiency, and safety of Pulse’s nPulse system in treating atrial fibrillation—key factors investors watch for medical devices seeking broader clinical adoption and commercialization. The updated investor deck makes these results readily available for analysts and potential partners, which may influence investor perception and ongoing development or regulatory planning.